Get Premium to unlock powerful stock data
OSL:ULTI (Norway)  
Ultimovacs ASA logo

Ultimovacs ASA

kr 69.40 (+2.28%) Jun 29
P/E:
At Loss
P/B:
4.28
Market Cap:
kr 2.37B ($ 241.04M)
Enterprise V:
kr 1.85B ($ 188.06M)
Volume:
23.66K
Avg Vol (2M):
37.04K
Also Trade In:
Volume:
23.66K
Market Cap kr:
2.37B
Market Cap $:
241.04M
PE Ratio:
At Loss
Avg Vol (2-Month):
37.04K
Enterprise Value kr:
1.85B
Enterprise Value $:
188.06M
PB Ratio:
4.28
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Name Current Vs Industry Vs History
Cash-To-Debt 301.33
Equity-to-Asset 0.93
Debt-to-EBITDA -0.01
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 59.82
9-Day RSI 52.91
14-Day RSI 49.83
6-1 Month Momentum % -29.09
12-1 Month Momentum % 2.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 15.59
Quick Ratio 15.59
Cash Ratio 15.34

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.1
Name Current Vs Industry Vs History
ROE % -34.76
ROA % -31.68
ROIC % -191.41
ROC (Joel Greenblatt) % -6340.66
ROCE % -33.37

Financials (Next Earnings Date:2022-08-19)

OSL:ULTI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 0
EPS (TTM) (kr) -5.2
Beta 1.38
Volatility % 70.58
14-Day RSI 49.83
14-Day ATR (kr) 4.435045
20-Day SMA (kr) 71.545
12-1 Month Momentum % 2.33
52-Week Range (kr) 60.5 - 170.2
Shares Outstanding (Mil) 34.22

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ultimovacs ASA Filings

Document Form Filing Date
No Filing Data